Opportunity ID: 332311

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-21-183
Funding Opportunity Title: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 23, 2021
Last Updated Date: Apr 01, 2021
Original Closing Date for Applications: Jan 10, 2024
Current Closing Date for Applications: Dec 06, 2023
Archive Date: Jan 05, 2024
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Private institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
State governments
Small businesses
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD, although there are other pathways for dissemination of this class of intervention. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-21-183.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date
Updated expiration date in accordance with NOT-DA-21-042 Apr 01, 2021
Mar 23, 2021

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-21-183
Funding Opportunity Title: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 23, 2021
Last Updated Date: Apr 01, 2021
Original Closing Date for Applications: Jan 10, 2024
Current Closing Date for Applications: Dec 06, 2023
Archive Date: Jan 05, 2024
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Private institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
State governments
Small businesses
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD, although there are other pathways for dissemination of this class of intervention. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-21-183.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-21-183
Funding Opportunity Title: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 23, 2021
Last Updated Date: Mar 23, 2021
Original Closing Date for Applications:
Current Closing Date for Applications: Jan 10, 2024
Archive Date: Feb 15, 2024
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Special district governments
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Independent school districts
Small businesses
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
State governments
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD, although there are other pathways for dissemination of this class of intervention. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-21-183.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Folder 332311 Full Announcement-PAR-21-183 -> PAR-21-183-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00266111 Jul 04, 2021 Jan 24, 2022 View
FORMS-G Use for due dates on or before January 24, 2023 PKG00270463 Nov 18, 2021 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00278433 Nov 15, 2022 Dec 06, 2023 View

Package 1

Mandatory forms

332311 RR_SF424_2_0-2.0.pdf

332311 PHS398_CoverPageSupplement_5_0-5.0.pdf

332311 RR_OtherProjectInfo_1_4-1.4.pdf

332311 PerformanceSite_2_0-2.0.pdf

332311 RR_KeyPersonExpanded_2_0-2.0.pdf

332311 RR_Budget_1_4-1.4.pdf

332311 PHS398_ResearchPlan_4_0-4.0.pdf

332311 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

332311 RR_SubawardBudget30_1_4-1.4.pdf

332311 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

332311 RR_SF424_5_0-5.0.pdf

332311 PHS398_CoverPageSupplement_5_0-5.0.pdf

332311 RR_OtherProjectInfo_1_4-1.4.pdf

332311 PerformanceSite_4_0-4.0.pdf

332311 RR_KeyPersonExpanded_4_0-4.0.pdf

332311 RR_Budget_3_0-3.0.pdf

332311 PHS398_ResearchPlan_4_0-4.0.pdf

332311 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

332311 RR_SubawardBudget30_3_0-3.0.pdf

332311 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

332311 RR_SF424_5_0-5.0.pdf

332311 PHS398_CoverPageSupplement_5_0-5.0.pdf

332311 RR_OtherProjectInfo_1_4-1.4.pdf

332311 PerformanceSite_4_0-4.0.pdf

332311 RR_KeyPersonExpanded_4_0-4.0.pdf

332311 RR_Budget_3_0-3.0.pdf

332311 PHS398_ResearchPlan_5_0-5.0.pdf

332311 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

332311 RR_SubawardBudget30_3_0-3.0.pdf

332311 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T20:30:24-05:00

Share This Post, Choose Your Platform!

About the Author: